Navigation Links
Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers
Date:2/10/2010

/gx/en/pharma-life-sciences/index.jhtml" onclick="linkClick( this.href );" target="_blank" title="Life Sciences">Life Sciences plunged 22 percent in 2009, while the number of deals dropped 19 percent during the same time period, marking its lowest point in the past six years. Despite the decline, Life Sciences investment has outpaced overall venture capital funding since the third quarter of 2008.

In the last quarter of 2009, biotechnology investments totaled $1 billion in 108 deals with another $719 million going into 87 medical device and equipment deals. Biotechnology funding declined by 7 percent year over year, primarily due to a drop in deal activity. However, funding for medical devices increased by 14 percent compared with the same quarter in 2008. This increase reflected gains in both deal activity and deal size.

Investments by Stage of Development
Early-stage funding for the Life Sciences sector exceeded $1 billion in the fourth quarter of 2009 for the first time. Increases in both deal activity and deal size resulted in this rise in early-stage investment. Late-stage funding declined to $717 million in the fourth quarter of 2009, compared with $1 billion in the same quarter in 2008. Late-stage deal activity and deal size both declined in this period.

"The need for venture capital is greater for early-stage companies that don't yet have an exit strategy. They need to funnel assets into the clinic to develop products that will make them attractive acquisitions or IPOs down the line," Lefteroff explained. "Later-stage companies are finding other ways to generate cash, such as partnerships and licensing agreements with larger companies looking to expand their product pipelines."

Funding by Subsegment
Historically, the biotech human subsegment has received a majority of the

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy , ... The GMO TRUTH podcast on both ITunes and at The ... mission to discover the truth and change the world. ... truth about the GMOs in our food supply,” adds a ... an expansion of the documentary/investigative film-making methodology in place at ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... 2011 Reportlinker.com announces that a new ... catalogue: Enzymes: Sustainable Alternatives ... http://www.reportlinker.com/p0501016/Enzymes-Sustainable-Alternatives-with-Remarkable-Scope.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Enzymes are among ... a whole host of different roles in ...
... four billion years of evolution, plants and animals grew ... new comparison of proteins shared across species finds that ... may have actually launched the long journey from microbe ... , suggests that the random introduction of errors into ...
... May 18, 2011 Biomerix Corporation and Cellon today ... 3D Scaffold , a novel three-dimensional tissue scaffold. Under ... 3D Scaffold to research institutions across Europe. ... polyurethane , the Biomerix 3D Scaffold is designed to ...
Cached Biology Technology:Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope 2Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope 3Errors in protein structure sparked evolution of biological complexity 2Errors in protein structure sparked evolution of biological complexity 3Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A. 2
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... University of Utah biology Professor Nalini Nadkarni is being ... the American Association for the Advancement of Science (AAAS) ... Award. The AAAS has issued the news release below: ... (AAAS) has named Nalini M. Nadkarni as the recipient ...
... A team of scientists, led by researchers at ... and Zacharon Pharmaceuticals, have developed a simple, reliable test ... inherited metabolic disorders that are currently diagnosed in patients ... possibly irreversible. The findings will be published online ...
... 8, 2012) The anxiety and behavioral issues associated with excess ... and Oprm 1 [mu-opioid receptor MOR 1]), which may point the ... the protein, said Baylor College of Medicine scientists in ... Genetics . Much of the work was done ...
Cached Biology News:Utah biologist wins 2011 AAAS Public Engagement with Science Award 2Utah biologist wins 2011 AAAS Public Engagement with Science Award 3New test spots early signs of inherited metabolic disorders 22 genes affect anxiety, behavior in mice with too much MeCP2 2
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
CBF-B (G-2)...
... polyclonal to Endothelin B Receptor Like ... Receptor-Like Protein 2 (ETBR-LP-2) has been ... been isolated from human brain and ... Synthetic peptide (unfortunately, the amino acid ...
Biology Products: